San Juan, November 4, 2021– miR Scientific announced at the Puerto Rico Urologists Conference that it will open a registry of patients who wish to receive the new miR Sentinel™ prostate cancer test, which the company hopes will be commercially available for public purposes. Persons interested in entering the registry should access and complete the following form: http://mirscientific.com/puertorico-info
As the time for commercialization of the tests approaches, Dr. Alvin Lopez Pugales, principal investigator of one of the miR Scientific clinical studies on the island, presented the results of a cross-validation study presented for the first time at the American Urological Association (AUA). The results confirmed that the miR Sentinel™ Prostate Cancer Test can detect prostate cancer and risk at the molecular level with a predictive accuracy of over 90% with a single urine sample. It also found that among recent clinical studies among patients in Puerto Rico, 50% to 70% of biopsies performed for prostate cancer could have been avoided.
Data presented in Puerto Rico by López Pujals and in the United States by Laurence Klotz, MD, Medical Director (CMO) at miR Scientific, are based on a study of 763 men 45 years of age or older, eligible for first biopsy. from the needle.
The main characteristics of the miR Sentinel™ assay are its high negative predictive value and high accuracy in identifying cancer. In addition to the fast response time, the test is highly scalable: a large number of tests can be performed at once. We hope that this new method for detecting prostate cancer will have a positive impact on patients all over the world and especially in Puerto Rico, which has the highest rates of prostate cancer in the world,” explained Lopez Bogals. This validation study confirms data from more than 1,400 patients published in the journal Urology in September 2020.
The Puerto Rican doctor, whose role in the clinical studies was instrumental, will present this data about the test soon in Dubai during the annual conference of the International Society of Urology (SIU).
About miR Scientific:
miR Scientific, LLC is a healthcare company committed to transforming global cancer management by providing early and highly accurate detection, characterization, and follow-up of these diseases. The company developed the miR Disease Management Platform®, a proprietary, non-invasive platform for the effective management of specific diseases, initially focused on urological cancers. The platform is powered by the miR Sentinel® Prostate Cancer Test, a liquid urine biopsy test that can accurately detect, classify and monitor prostate cancer based on interrogation of small non-coding RNA extracted from urinary exosomes.
miR Scientific develops products needed to revolutionize standards of care that support urological tumors, including prostate, bladder, and other urothelial cancers. These new standards are urgently needed given the prevalence and debilitating burden of these cancers globally. miR Scientific is a majority-owned operating company of Impact NRS LLC, headquartered in New York City with subsidiary operating companies in Israel, Canada and Puerto Rico.
